UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **May 3, 2016**

AMICUS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	
(State or Other Jurisdiction of Incorporation)	
001-33497	**71-0869350**
(Commission File Number)	(IRS Employer Identification No.)
1 Cedar Brook Drive, Cranbury, NJ	**08512**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(609) 662-2000**

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On May 3, 2016, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2016. A copy of this press release is attached hereto as Exhibit 99.1. The Company will also host a conference call and webcast on May 3, 2016 to discuss its first quarter results of operations. A copy of the conference call presentation materials is also attached hereto as Exhibit 99.2.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amicus Therapeutics, Inc.

Date: May 3, 2016

By: /s/ Ellen S. Rosenberg
Ellen S. Rosenberg
General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated May 3, 2016
99.2	May 3, 2016 Conference Call Presentation Materials

Amicus Therapeutics Announces First Quarter 2016 Financial Results and Corporate Updates

Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations

Actively Enrolling Patients Across Multiple Sites in Clinical Study to Investigate Novel Enzyme Replacement Therapy for Pompe Disease

Company to Remain Within Original Full-Year 2016 Net Cash Spend Guidance of $135M-$155M

CRANBURY, NJ, May 3, 2016 — Amicus Therapeutics (Nasdaq: FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the first quarter ended March 31, 2016. The Company also provided program updates and reiterated full-year 2016 net cash spend guidance.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "At Amicus we have a clear vision to build a leading global biotechnology company focused on rare and devastating diseases. The positive CHMP opinion in Europe was a pivotal event for our company and for people living with Fabry disease. Our extraordinary international commercial team now stands ready to launch migalastat upon formal EC adoption. We also remain committed to advancing therapies for all patients with Fabry disease, including those with mutations that are non-amenable to migalastat. Thus, following the positive CHMP Opinion last month, we have also selected a novel Fabry ERT cell line to move forward in development for patients with these non-amenable mutations. With these two products, a precision medicine small molecule and a novel ERT, our vision is to have a medicine available to help all Fabry patients. Indeed, we believe that today our three lead clinical programs in Fabry, Pompe and EB each have the potential to extend and enhance the lives of people living with these respective disorders. This mission is our passion and our focus."

First Quarter 2016 Financial Results

- Cash, cash equivalents, and marketable securities totaled $165.9 million at March 31, 2016 compared to $214.0 million at December 31, 2015.
- Total operating expenses in the first quarter of 2016 increased to $43.0 million compared to $24.1 million for the first quarter 2015 primarily due to increases in pre-commercial costs for the Fabry monotherapy program, the addition of the SD-101 program for EB, as well as manufacturing scale-up and clinical trial costs for the Pompe program.
- Net loss was $43.7 million, or $0.35 per share, compared to a net loss of $24.3 million, or $0.25 per share, for the first quarter 2015.

2016 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $165.9 million at March 31, 2016. The Company's balance sheet was strengthened during the second quarter of 2016 with $16.2 million in net proceeds under the existing at-the-marketing (ATM) financing facility. In addition, the Company plans to access an additional $10.0 million under an existing debt facility.

Based on a detailed financial review after the positive CHMP opinion and through the continued careful management of expenses, the Company expects to remain within the original 2016 net cash spend guidance of between $135 million and $155 million. The current cash position, including proceeds raised from the ATM and the additional debt, is projected to fund operations into mid-2017.

Program Highlights

Migalastat for Fabry Disease

Migalastat is an oral personalized medicine intended to treat Fabry disease in patients who have amenable genetic mutations. Amicus has built a commercial organization that is prepared to launch migalastat upon approval in the EU and other international territories.

On April 1, 2016, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in favor of approval of migalastat as a first line therapy for Fabry disease in all patients who have an amenable genetic mutation. The label approved by the CHMP includes 269 Fabry causing amenable mutations, which represent up to half of all patients with Fabry disease.

The proposed indication for migalastat is for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. A final decision from the European Commission (EC) is expected in the second quarter of 2016, after which the Company will begin the country-by-country reimbursement processes.

In the U.S., Amicus has substantially completed the Integrated Safety Summary across all clinical studies as requested by the U.S. Food and Drug Administration (FDA). New data analyses include gastrointestinal symptom data as well as histopathology data and longer-term renal and cardiac data across both Phase 3 clinical studies that were presented at WORLD*Symposium*™ 2016. The Company anticipates meeting with the FDA in mid-2016 to present these data and discuss a potential pathway to submit a New Drug Application (NDA) for migalastat in the U.S.

On the heels of a positive CHMP Opinion, Amicus is committed to delivering the highest quality therapies for all patients with Fabry disease beginning with migalastat as a personalized medicine for Fabry patients with amenable mutations. For patients with non-amenable mutations, the Company is leveraging its CHART technology and advanced biologics capabilities to move forward with a proprietary Fabry ERT cell line for co-formulation with migalastat. Master cell banking is now complete and process development work is underway. The Company intends to provide preclinical data and more information on the development pathway for this novel ERT in Fabry disease in the second half of 2016.

Anticipated Upcoming Fabry Disease Program Milestones:

- EC adoption and EU launch
- Expanded Access Program (EAP) in additional international territories
- Publication of Phase 3 Clinical Study 011 data
- FDA meeting and U.S. regulatory update
- Fabry ERT cell line development and preclinical data

ATB200/AT2221 for Pompe Disease

Patient dosing has begun in a global clinical study (ATB200-02) to investigate ATB200/AT2221, a novel treatment paradigm that consists of ATB200, a uniquely engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, a pharmacological chaperone to improve activity and stability. Up to approximately a dozen clinical sites are expected to participate in this study.

Anticipated 2016 Pompe Disease Program Milestones:

- Interim data from clinical study ATB200-02

SD-101 for Epidermolysis Bullosa (EB)

SD-101 is a novel, late-stage, proprietary topical treatment and potential first-to-market therapy for EB. SD-101 is currently being investigated in a registration-directed Phase 3 study (ESSENCE, also known as SD-005) to support global regulatory submissions. The company began a rolling NDA submission for SD-101 in the fourth quarter of 2015.

SD-101 was granted FDA Breakthrough Therapy designation in 2013 based on results from a Phase 2a study for the treatment of lesions in patients suffering with EB. SD-101 is the first-ever treatment in clinical studies to show improvements in wound closure across all major EB types.

Anticipated 2016 EB Program Milestones:

- Phase 2b (Study SD-003) data poster at Society of Investigative Dermatology's (SID) 2016 SID Annual Meeting in Scottsdale, AZ from May 11-14, 2016
- Completion of enrollment in Phase 3 study

- Top-line Phase 3 data

Conference Call and Webcast

Amicus Therapeutics will host a conference call and audio webcast today, May 3, 2016 at 8:30 a.m. ET to discuss first quarter 2016 financial results and corporate updates. Interested participants and investors may access the conference call at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

An audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET today. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 98970481.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, financing plans, and the projected cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities,

and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials and the expected timing of the EMA's final decision with respect to regulatory approval of migalastat in the European Union, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the EMA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing our product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino
Senior Director, Investor Relations
spellegrino@amicusrx.com
(609) 662-5044

Media:
Pure Communications
Dan Budwick
dan@purecommunicationsinc.com
(973) 271-6085

Table 1

Amicus Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)

	Three Months Ended March 31,	
	2016	**2015**
Operating Expenses:		
Research and development	$ 23,425	$ 16,113
General and administrative	15,701	6,427
Changes in contingent consideration payable	3,152	1,000
Restructuring charges	50	10
Depreciation	673	508
Total operating expenses	43,001	24,058
Loss from operations	(43,001)	(24,058)
Other income (expenses):		
Interest income	307	171
Interest expense	(945)	(372)
Other expense	(52)	(29)
Net loss	$ (43,691)	$ (24,288)
Net loss per common share — basic and diluted	$ (0.35)	$ (0.25)
Weighted-average common shares outstanding — basic and diluted	125,178,517	95,743,416

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)

	March 31, 2016	December 31, 2015
Assets:		
Current assets:		
Cash and cash equivalents	$ 23,510	$ 69,485
Investments in marketable securities	142,341	144,548

Prepaid expenses and other current assets	2,662	2,568
Total current assets	168,513	216,601
Property and equipment, less accumulated depreciation and amortization of $13,996 and $13,353 at March 31, 2016 and December 31, 2015, respectively	8,413	6,178
In-process research & development	486,700	486,700
Goodwill	197,797	197,797
Other non-current assets	1,484	1,108
Total Assets	$ 862,907	$ 908,384
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable and accrued expenses	$ 22,501	$ 32,216
Current portion of contingent consideration payable	41,926	41,400
Total current liabilities	64,427	73,616
Deferred reimbursements	35,756	35,756
Due to related party	38,509	41,601
Contingent consideration payable, less current portion	235,303	232,677
Deferred tax liability	176,219	176,219
Other non-current liability	1,061	681
Commitments and contingencies		
Stockholders' equity:		
Common stock, $.01 par value, 125,000,000 shares authorized, 125,221,637 shares issued and outstanding at March 31, 2016, 125,000,000 shares authorized, 125,027,034 shares issued and outstanding at December 31, 2015	1,308	1,306
Additional paid-in capital	921,234	917,454
Accumulated other comprehensive loss:		
Foreign currency translation adjustment	(65)	—
Unrealized gain/(loss) on available for sale securities	114	(115)
Warrants	12,298	8,755
Accumulated deficit	(623,257)	(579,566)
Total stockholders' equity	311,632	347,834
Total Liabilities and Stockholders' Equity	$ 862,907	$ 908,384

FOLD—G

Exhibit 99.2

Amicus Therapeutics®

1Q16 Financial Results Conference Call & Webcast

May 3, 2016

Safe Harbor

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, financing plans, and the projected cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials and the expected timing of the EMA's final decision with respect to regulatory approval of migalastat in the European Union, actual results may differ materially from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the EMA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing our product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Key Drivers of Value

3 Novel Product Candidates Each with $500M to $1B+ Market Potential

Fabry

- Migalastat Personalized Medicine (Small Molecule)
- Positive CHMP Opinion (April 1, 2016)
- EC Adoption and EU Launch*
- FDA meeting expected mid-year 2016

Epidermolysis Bullosa (EB)

- Phase 3 Novel Topical Treatment (SD-101)
- U.S. Breakthrough Therapy Designation
- Rolling NDA
- Phase 3 Data Expected in 2H16

Pompe

- Novel ERT + Chaperone Treatment Paradigm
- Biologics Manufacturing
- Clinical Study Initiated with Interim Data Anticipated in 2016

R&D Engine and Continued Business Development Activity

*Pending Approval

Amicus Therapeutics

Amicus 2016 – Continuing the Momentum

Significant Milestones in 2016



Amicus Therapeutics

Migalastat Personalized Medicine for Fabry Disease

Positive CHMP Opinion Recommending Broad Label for Migalastat

Migalastat Indicated for Long-Term Treatment of Adults and Adolescents Aged ≥ 16 years with a Confirmed Diagnosis of Fabry Disease and Who have an Amenable Mutation

1 April 2016
EMA/CHMP/224720/2016
Press office

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Press release

First oral treatment for Fabry disease recommended for approval in the EU

Galafold to provide additional treatment option for this rare genetic disease

The evaluation of EMA's Committee for Medicinal Products for Human Use (CHMP) was based on the results of two phase III clinical trials in about 110 patients with Fabry disease who had a genetic mutation which responds to migalastat. Galafold demonstrated its efficacy compared to placebo (a dummy treatment) and to ERT in a long-term comparative study.

- EMA Press Release

Launch Preparation Activities

- Medical education and patient advocacy ongoing on behalf of Fabry patients
- Experienced commercial leadership team with established international operations
- Patient and physician mapping
- Global value dossier complete and local submissions initiated
- International distribution system

Amicus is Prepared for 2016 Launch

Amicus Therapeutics

Fabry Market Today

Amicus is Prioritizing EU, Japan, US and Other Large Fabry Markets for Initial Launch

$1.2B in FY15 ERT Sales[1]



- 40-50% of Diagnosed Patients Not on ERT Today
- Market Continues to Grow > 10% / Year
- ERT Infused Once Every 2 Weeks

- ***First*** new product in > 10 years
- ***First*** oral therapy
- ***First*** targeted therapy for amenable patients (30%-50% of population)

1. Company filings and Amicus estimates

Amicus Therapeutics

Global Regulatory Strategy

EU Approval Lays the Foundation to Address ~70% of Global Fabry Market



Amicus Therapeutics

Japan Market Overview

Amicus is Actively Pursuing a Regulatory Pathway in Japan

MARKET OVERVIEW

- ~650 patients treated
- No ERT home infusion currently available
- Physicians tend to initiate treatment early

CLINICAL/REGULATORY STATUS

- Phase 1 PK study completed
- Multiple sites and patients participated in Phase 3 Study 012
- Orphan drug designation
- Regulatory discussions initiated with PMDA

Amicus Therapeutics

Significant Underdiagnosis of Fabry Disease

Larger Number of Patients Identified Through Newborn Screening Suggest Fabry Could be One of the More Prevalent Human Genetic Diseases

Newborn Screening Study	# Newborns Screened	# Confirmed Fabry Mutations	% Amenable
Burton, 2012, US	8,012	7 [1: ~1100]	TBD
Mechtler, 2011, Austria	34,736	9 [1: ~3,800]	100%
Hwu, 2009, Taiwan	171,977	75 [1: ~2300]	75%
Spada, 2006, Italy	37,104	12 [1: ~3100]	86%
Historic published incidence		**1:40,000 to 1:60,000**	

Index Patient
(3-5:1 Index)



Majority of Newly Diagnosed Patients Have Amenable Mutations

Burton, **LDN WORLD Symposium,** 2012 Feb.
Mechtler *et al.*, **The Lancet**, 2011 Dec.

Hwu *et al.*, **Hum Mutation**, 2009 Jun
Spada *et al.*, **Am J Human Genet.**, 2006 Jul

Amicus Therapeutics

Amicus Proprietary Fabry ERT



Fabry Franchise Strategy

Amicus Therapeutics is Committed to Delivering the Highest Quality Therapies and Future Innovation to Find a Cure for ALL Fabry Patients





ATB200 Novel ERT for Pompe Disease

A Proprietary, Clinical-Stage Biologics Program

Pompe ERT - 3 Challenges

Amicus Technology Platforms with Potential to Address Challenges with Existing Pompe ERT

Activity/ Stability

Rapid denaturation of ERT in pH of blood[1]

Protein Aggregation

CHART
CHAPERONE-ADVANCED REPLACEMENT THERAPY

Tolerability / Immunogenicity

Infusion-associated reactions in >50% of late-onset patients[3]

Antibody titers shown to affect treatment outcomes[4,5]

CHART
CHAPERONE-ADVANCED REPLACEMENT THERAPY

Uptake/ Targeting

Low M6P receptor uptake into skeletal muscle[2]

Vast majority of rhGAA not delivered to lysosomes[2]



Uniquely Engineered rhGAA Optimized M6P & Carbohydrates

1Khanna et al., PLoS ONE, 2012; 2Zhu et al., Amer. Soc. Gene Therapy, 2009 June; 3Banati et al., Muscle Nerve, 2011 Dec.; 4Banugaria et al., Gen. Med., 2011 Aug.; 5de Vries et al., Mol Genet Metab., 2010 Dec.

Amicus Therapeutics

Biologics Manufacturing Capabilities

Optimized Glycosylation and Key Quality Attributes Maintained Through Scale Up

CI-MPR Receptor Chromatography



Lyophilized Vial of ATB200



Amicus Therapeutics

Pompe Program Update

Progress Continues in Phase 1/2 Pompe ATB200/AT2221 Co-Administration Study (ATB200-02)

PHASE 1/2 STUDY STATUS

- Multiple Sites Opened
- Actively Dosing Patients
- Enrollment Ongoing
- Interim Data Expected 2H16



SD-101 for Epidermolysis Bullosa (EB)

Poised to deliver pivotal data for a devastating rare disease in 2016

EB Program Update

Enrollment Continues at 16 Sites Globally with Top-Line Data Anticipated 2H16



PHASE 3 STUDY STATUS

- >50% of target enrollment achieved
- 100% conversion to extension study (SD-006)
- Top-line Phase 3 data anticipated in 2H16



Financial Summary

Strong Balance Sheet to Invest in Rare Disease Pipeline

Strong Balance Sheet

Strong Balance Sheet Provides Cash Runway into Mid-2017

Financial Position	March 31, 2016
Current Cash:	$165.9M
Current Debt	$50.0M
FY16 Net Cash Spend Guidance:	$135-$155M
Cash Runway	Mid-2017
Total Net Proceeds from ATM as of April 29	$16.2M
Capitalization	
Shares Outstanding	125,221,637

1Q16 Select Financial Results

($000s)	March 31, 2016	March 31, 2015
R&D Expense	23,425	16,113
G&A Expense	15,701	6,427
Net Loss	(43,691)	(24,288)
Net Loss Per Share	(0.35)	(0.25)

Amicus Vision

Amicus Therapeutics is a global biotechnology company at the forefront of developing advanced therapies to treat a range of devastating rare and orphan diseases

Thank You

Amicus Therapeutics®